Description: Ovid Therapeutics Inc., a biopharmaceutical company, develops impactful medicines for patients and families with neurological disorders in the United States. The company is developing OV101, a drug candidate, which is in Phase 2A clinical trials for the treatment of fragile X syndrome; OV329, a GABA aminotransferase inhibitor for the treatment of seizures associated with tuberous sclerosis complex and infantile spasms; and OV350, a small molecule for treating epilepsies. It also develops OV882, a short hairpin RNA gene therapy for the treatment of angelman syndrome; and OV815 for the treatment of kinesin-family of proteins associated neurological disorder. The company has license and collaboration agreements with Healx, AstraZeneca AB, H. Lundbeck A/S, and Northwestern University, as well as Marinus Pharmaceuticals, Inc. The company was incorporated in 2014 and is headquartered in New York, New York.
Home Page: www.ovidrx.com
1460 Broadway
New York,
NY
10036
United States
Phone:
646 661 7661
Officers
| Name | Title |
|---|---|
| Dr. Jeremy Max Levin Ba Zoology, Dphil, Mb Bchir | Pres, CEO & Chairman |
| Mr. Jeffrey A. Rona | Principal Financial Officer, Principal Accounting Officer & Chief Bus. and Financial Officer |
| Mr. Thomas Michael Perone J.D., M.B.A. | Gen. Counsel, Chief Compliance Officer & Corp. Sec. |
| Dr. Matthew J. During DSc, FACP, FRACP, M.D., Ph.D. | Founder & Member of Scientific Advisory Board |
| Mr. Jason Tardio M.B.A. | Chief Operating Officer |
| Ms. Lora Pike | Sr. Director of Investor Relations & PR |
| Mr. Simon D. Kelner | Sr. VP & Chief HR Officer |
| Dr. Dirk Haasner | Sr. VP of Global Manufacturing & CMC QA |
| Ms. Suzanne K. Wakamoto SHRM-SCP, SPHR | Sr. VP of Culture & Facilities |
| Dr. Claude Nicaise M.D. | Head of R&D |
Exchange: F
Country: DE
Currency: Euro (€)
| Forward PE: | 1.7486 |
|---|---|
| Trailing PE: | 0 |
| Price-to-Book MRQ: | 0.8805 |
| Price-to-Sales TTM: | 81.2617 |
| IPO Date: | |
| Fiscal Year End: | December |
| Full Time Employees: | 44 |